



News Release

Suven enters into collaboration with University of Minnesota To Develop Drugs To Treat HIV infection.

HYDERABAD, INDIA (October 25th, 2007) – SUVEN Life Sciences Ltd (Suven) enters into collaboration with University of Minnesota, Minneapolis, USA aimed at developing new therapies to treat the life threatening disease human immunodeficiency virus type 1 (HIV-1).

This collaboration in principle is co-operating in a research and test program to explore clinical efficacy of, and make available to patients, under safe conditions, certain naturally- occurring substances that are believed to have therapeutic value for HIV-1.

HIV is a retrovirus that can lead to Acquired Immunodeficiency Syndrome (AIDS). HIV infection in humans is now a pandemic. It is estimated that 0.6% of global population is infected with HIV, mainly in Africa and Indian Sub continent. Current antiretroviral therapy is not only costly but also not accessible to many parts of the world.

Hence a desperate worldwide need for additional therapies to treat HIV-1 cost effectively is the need of the hour and collaborating with University of Minnesota Infectious Diseases and International medicine group to develop drugs to meet this requirement by using natural resources enthused us to enter into this collaboration says Venkat Jasti , CEO of Suven Life Sciences.

Dr. Phillip Peterson, Director, Center for Infectious Diseases and Microbiology Translational Research and Dr. Ramaiah Muthyala, Associate Director, Center for Orphan Drug Research, College of Pharmacy of University of Minnesota stated that they were particularly impressed with the shared mission and vision of their centers and Suven, i.e., to translate discoveries into inexpensive therapies that could be available to masses for the treatment and prevention of life threatening diseases like HIV and AIDS.

Suven Life Sciences is a Hyderabad based Life Sciences Company a **Collaborative Research Partner (CRP)** since 2006 in **Drug Discovery** for global pharma major is a pioneer in **Contract Research and Manufacturing Services (CRAMS)** since 1995 and **Drug Discovery Development Support Services (DDDSS)** since 2005. Suven has been involved in development of path breaking technologies for global pharma companies for more than a decade.

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;